The Univeristy Of Texas M.D.
Anderson Cancer Center
CAGE Code: 0KD38
NCAGE Code: 0KD38
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 800772139
Summary
The Univeristy Of Texas M.D., Anderson Cancer Center is an Active Commercial Supplier with the Cage Code 0KD38 and is tracked by Dun & Bradstreet under DUNS Number 800772139..
Address
1515 Holcombe Blvd
Houston TX 77030-4009
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Mmlj Inc Abv Graphics Inc Tenneco Technology Services Inc Aquaterra Engineering Inc Yogurt Technologies Thoroughenvironmental Services Inc Amsi Intl Trading Corp System Integration And Installations Bmc Software, Inc. Alloy Chile Llc Rhdix Press Wyatt Inc Subsidiary Of U S Specialty Products And Insulation Co Quality Turbocharger Components Llc Omnispec Corp Harco Technologies Corp Integrated Command Software Inc Radx Corp Grinnell Fire Protection Argos Technologies, Inc.
Frequently Asked Questions (FAQ) for CAGE 0KD38
- What is CAGE Code 0KD38?
- 0KD38 is the unique identifier used by NATO Organizations to reference the physical entity known as The Univeristy Of Texas M.D. Anderson Cancer Center located at 1515 Holcombe Blvd, Houston TX 77030-4009, United States.
- Who is CAGE Code 0KD38?
- 0KD38 refers to The Univeristy Of Texas M.D. Anderson Cancer Center located at 1515 Holcombe Blvd, Houston TX 77030-4009, United States.
- Where is CAGE Code 0KD38 Located?
- CAGE Code 0KD38 is located in Houston, TX, USA.
Contracting History for CAGE 0KD38 Most Recent 25 Records
- 75F40123P00335
- Center For Biologics Evaluation And Research Duration Of Pertussis Immunity In Baboons Study
- 31 Aug 2023
- Center For Biologics Evaluation And Research Duration Of Pertussis Immunity In Baboons Study
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $171,069.00
- Department Of Health And Human Services (Hhs)
- 75N91023F00003
- Targeting The A2b Adenosine Receptor For Immunoprevention Of Pancreatic Cancer
- 12 Sep 2023
- Targeting The A2b Adenosine Receptor For Immunoprevention Of Pancreatic Cancer
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $593,572.00
- Department Of Health And Human Services (Hhs)
- 75N91023F00001
- Further Development Of Ipsc-Based Vaccine For Colon Cancer Prevention
- 5 Sep 2023
- Further Development Of Ipsc-Based Vaccine For Colon Cancer Prevention
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,293,012.00
- Department Of Health And Human Services (Hhs)
- 75N91023F00001
- Further Development Of Ipsc-Based Vaccine For Colon Cancer Prevention
- 20 Jul 2023
- Further Development Of Ipsc-Based Vaccine For Colon Cancer Prevention
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,293,012.00
- Department Of Health And Human Services (Hhs)
- 75N91023F00002
- Targeting Dkk1 With A Dna Vaccine To Prevent Development Of Multiple Myeloma
- 20 Jun 2023
- Targeting Dkk1 With A Dna Vaccine To Prevent Development Of Multiple Myeloma
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,101,494.00
- Department Of Health And Human Services (Hhs)
- 75F40122P00381
- A Study In Which Twelve Baboons That Have Recovered From B. Pertussis Infection Will Be Housed And Followed For One Year In Order To Assess Duration Of B. Pertussis Immune Responses.
- 9 Sep 2022
- A Study In Which Twelve Baboons That Have Recovered From B. Pertussis Infection Will Be Housed And Followed For One Year In Order To Assess Duration Of B. Pertussis Immune Responses.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $143,340.00
- Department Of Health And Human Services (Hhs)
- 75N98022F00002
- Rhesus, Indian Origin, Even Gender, - 2 Yrs Of Age, Spf Iaw Rfq Nc42. (75N98021d00018)
- 16 Jul 2022
- Rhesus, Indian Origin, Even Gender, - 2 Yrs Of Age, Spf Iaw Rfq Nc42. (75N98021d00018)
- National Institutes Of Health Olao
- Department Of Health And Human Services (Hhs)
- $255,964.80
- Department Of Health And Human Services (Hhs)
- 75N91022F00002
- Targeting Stat3 To Prevent Non-Small Cell Lung Cancer (Nsclc) In Patients With Chronic Obstructive Pulmonary Disease (Copd)
- 20 Sep 2022
- Targeting Stat3 To Prevent Non-Small Cell Lung Cancer (Nsclc) In Patients With Chronic Obstructive Pulmonary Disease (Copd)
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,097,981.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00002
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoints Biomarkers Task Order Title: Targeting Stat3 To Prevent Non-Small Cell Lung Cancer (Nsclc) In Patients With Chronic Obstructive Pulmonary Disease
- 31 May 2023
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoints Biomarkers Task Order Title: Targeting Stat3 To Prevent Non-Small Cell Lung Cancer (Nsclc) In Patients With Chronic Obstructive Pulmonary Disease
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,097,981.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00002
- Targeting Stat3 To Prevent Non-Small Cell Lung Cancer (Nsclc) In Patients With Chronic Obstructive Pulmonary Disease (Copd)
- 8 Sep 2022
- Targeting Stat3 To Prevent Non-Small Cell Lung Cancer (Nsclc) In Patients With Chronic Obstructive Pulmonary Disease (Copd)
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,097,981.00
- Department Of Health And Human Services (Hhs)
- 75N98022F00001
- Per Diem And Testing Cost For The Niaid Owl Monkey Colony
- 20 May 2022
- Per Diem And Testing Cost For The Niaid Owl Monkey Colony
- National Institutes Of Health Olao
- Department Of Health And Human Services (Hhs)
- $70,000.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00001
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Targeting The Parp Pathway For The Prevention Of Breast Cancer (2022 E-01)
- 30 Jun 2022
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Targeting The Parp Pathway For The Prevention Of Breast Cancer (2022 E-01)
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,121,090.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00001
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Targeting The Parp Pathway For The Prevention Of Breast Cancer (2022 E-01)
- 23 May 2023
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Targeting The Parp Pathway For The Prevention Of Breast Cancer (2022 E-01)
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,121,090.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00001
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers-- Targeting The Parp Pathway For The Prevention Of Breast Cancer
- 24 May 2022
- Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers-- Targeting The Parp Pathway For The Prevention Of Breast Cancer
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,121,090.00
- Department Of Health And Human Services (Hhs)
- 75N98021F00002
- Per Diem And Testing Of The Niaid Owl Monkey Colony (Md Anderson 75N98021d00018)
- 8 Sep 2021
- Per Diem And Testing Of The Niaid Owl Monkey Colony (Md Anderson 75N98021d00018)
- National Institutes Of Health Olao
- Department Of Health And Human Services (Hhs)
- $90,000.00
- Department Of Health And Human Services (Hhs)
- 75N98021F00001
- Squirrel Monkey, Bolivian, Either Gender, Greater Than 750 Gram, Spf, Iaw Rfq N60 (Md Anderson 75N98021d00018)
- 8 Sep 2021
- Squirrel Monkey, Bolivian, Either Gender, Greater Than 750 Gram, Spf, Iaw Rfq N60 (Md Anderson 75N98021d00018)
- National Institutes Of Health Olao
- Department Of Health And Human Services (Hhs)
- $32,070.00
- Department Of Health And Human Services (Hhs)
- 75F40121C00180
- Immunogenicity Study In Baboons Following Vaccination With Experimental Acellular Pertussis Vaccines.
- 28 Sep 2021
- Immunogenicity Study In Baboons Following Vaccination With Experimental Acellular Pertussis Vaccines.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $273,005.00
- Department Of Health And Human Services (Hhs)
- 75F40121C00180
- Immunogenicity Study In Baboons Following Vaccination With Experimental Acellular Pertussis Vaccines.
- 28 Sep 2021
- Immunogenicity Study In Baboons Following Vaccination With Experimental Acellular Pertussis Vaccines.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $273,005.00
- Department Of Health And Human Services (Hhs)
- 75F40121C00180
- Immunogenicity Study In Baboons Following Vaccination With Experimental Acellular Pertussis Vaccines.
- 19 Feb 2023
- Immunogenicity Study In Baboons Following Vaccination With Experimental Acellular Pertussis Vaccines.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $547,054.00
- Department Of Health And Human Services (Hhs)
- 36C24521C0180
- Eo14042 - Vaccine Mandate -Peer Review Of Radiation Therapy
- 3 Jan 2022
- Eo14042 - Vaccine Mandate -Peer Review Of Radiation Therapy
- 245-Network Contract Office 5 (36C245)
- Department Of Veterans Affairs (Va)
- $320,500.00
- Department Of Veterans Affairs (Va)
- 36C24521C0180
- Medical Physics Peer Review Of Radiation Therapy Quality Assurance Operations
- 27 Sep 2021
- Medical Physics Peer Review Of Radiation Therapy Quality Assurance Operations
- 245-Network Contract Office 5 (36C245)
- Department Of Veterans Affairs (Va)
- $320,500.00
- Department Of Veterans Affairs (Va)
- 36C24521C0180
- Decrease Mod - Peer Review Of Radiation Therapy
- 19 Apr 2023
- Decrease Mod - Peer Review Of Radiation Therapy
- 245-Network Contract Office 5 (36C245)
- Department Of Veterans Affairs (Va)
- $654,850.00
- Department Of Veterans Affairs (Va)
- 36C24521C0180
- Oy 2- Peer Review Of Radiation Therapy
- 26 Jul 2023
- Oy 2- Peer Review Of Radiation Therapy
- 245-Network Contract Office 5 (36C245)
- Department Of Veterans Affairs (Va)
- $1,014,430.00
- Department Of Veterans Affairs (Va)
- 75N91021F00002
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy & Intermediate Biomarkers Task Order Title: Targeting Stat3 To Prevent Colorectal Cancer Secondary To Inflammatory Bowel Disease
- 10 Aug 2023
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy & Intermediate Biomarkers Task Order Title: Targeting Stat3 To Prevent Colorectal Cancer Secondary To Inflammatory Bowel Disease
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $932,948.00
- Department Of Health And Human Services (Hhs)
- 75N91021F00002
- Targeting Stat3 To Prevent Colorectal Cancer Secondary To Inflammatory Bowel Disease
- 14 Dec 2021
- Targeting Stat3 To Prevent Colorectal Cancer Secondary To Inflammatory Bowel Disease
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $932,948.00
- Department Of Health And Human Services (Hhs)